Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability
作者:Aaron D. Schuler、Courtney A. Engles、Dean Y. Maeda、Mark T. Quinn、Liliya N. Kirpotina、Winston N. Wicomb、S. Nicholas Mason、Richard L. Auten、John A. Zebala
DOI:10.1016/j.bmcl.2015.07.090
日期:2015.9
The chemokine receptors CXCR1 and CXCR2 are important pharmaceutical targets due to their key roles in inflammatory diseases and cancer progression. We have previously identified 2-[5-(4-fluoro-phenylcarbamoyl)-pyridin-2-ylsulfanylmethyl]-phenylboronic acid (SX-517) and 6-(2-boronic acid-5-trifluoromethoxy-benzylsulfanyl)-N-(4-fluoro-phenyl)-nicotinamide (SX-576) as potent non-competitive boronic acid-containing CXCR1/2 antagonists. Herein we report the synthesis and evaluation of aminopyridine and aminopyrimidine analogs of SX-517 and SX-576, identifying (2-(benzyl)[(5-boronic acid-2pyridyl) methyl] amino}-5-pyrimidinyl)(4-fluorophenylamino) formaldehyde as a potent chemokine antagonist with improved aqueous solubility and oral bioavailability. (C) 2015 Elsevier Ltd. All rights reserved.
Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators
申请人:Maeda Dean Y.
公开号:US20120046243A1
公开(公告)日:2012-02-23
There is disclosed aminopyridine-and aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.